Drugs that contain Darolutamide
1. Drug name - NUBEQA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8975254 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(8 years from now) | |
| US9657003 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(8 years from now) | |
| US11046713 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(8 years from now) | |
| US10711013 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(8 years from now) | |
| US10383853 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(13 years from now) | |
| US10010530 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(13 years from now) | |
| US11168058 | BAYER HEALTHCARE | Manufacture of a crystalline pharmaceutical product |
Feb, 2038
(15 years from now) | |
| CN101410016A | BAYER HEALTHCARE | Fungicidal Compositions |
Feb, 2027
(4 years from now) | |
| CN101410016B | BAYER HEALTHCARE | Fungicidal Compositions |
Feb, 2027
(4 years from now) | |
| CN102596910B | BAYER HEALTHCARE | Androgen Receptor Modulator Compounds |
Oct, 2030
(8 years from now) | |
| CN102596910A | BAYER HEALTHCARE | Androgen Receptor Modulator Compounds |
Oct, 2030
(8 years from now) | |
| CN105061313B | BAYER HEALTHCARE | Androgen Receptor Modulator Compounds |
Oct, 2030
(8 years from now) | |
| CN105061313A | BAYER HEALTHCARE | Androgen Receptor Regulation Compound |
Oct, 2030
(8 years from now) | |
| IN304033B | BAYER HEALTHCARE | Androgen Receptor Modulating Compounds |
Oct, 2030
(8 years from now) | |
| IN201200848P2 | BAYER HEALTHCARE | Androgen Receptor Modulating Compounds |
Oct, 2030
(8 years from now) | |
| EP1986495A2 | BAYER HEALTHCARE | Fungicidal Compositions |
Feb, 2027
(4 years from now) | |
| EP1986495B1 | BAYER HEALTHCARE | Fungicidal Compositions |
Feb, 2027
(4 years from now) | |
| EP3056485B1 | BAYER HEALTHCARE | Androgen Receptor Modulating Compounds |
Oct, 2030
(8 years from now) | |
| EP3369732B1 | BAYER HEALTHCARE | Androgen Receptor Modulating Compounds |
Oct, 2030
(8 years from now) | |
| EP3369732A1 | BAYER HEALTHCARE | Androgen Receptor Modulating Compounds |
Oct, 2030
(8 years from now) | |
| EP3056485A1 | BAYER HEALTHCARE | Androgen Receptor Modulating Compounds |
Oct, 2030
(8 years from now) | |
| EP2493858B1 | BAYER HEALTHCARE | Androgen Receptor Modulating Compounds |
Oct, 2030
(8 years from now) | |
| EP2493858A1 | BAYER HEALTHCARE | Androgen Receptor Modulating Compounds |
Oct, 2030
(8 years from now) | |
| EP3250554A1 | BAYER HEALTHCARE | A Carboxamide Derivative And Its Diastereomers In Stable Crystalline Form |
Jan, 2036
(13 years from now) | |
| EP3250554B1 | BAYER HEALTHCARE | A Carboxamide Derivative And Its Diastereomers In Stable Crystalline Form |
Jan, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10835515 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(13 years from now) | |
Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 300MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.